Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12440995 | 0.87 | TTR (0.40) | ACHEALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL15183455 | 0.85 | ACHE (0.50) | ACHEALDH1A1KDM4ECYP19A1CYP3A4 | |
| SCHEMBL13605941 | 0.84 | TDP1 (0.48) | ACHEALDH1A1KDM4ETDP1CYP3A4 | |
| SCHEMBL440813 | 0.77 | HSD17B10 (0.47) | ALDH1A1KDM4ETDP1MAPTTPMT | |
| SCHEMBL10030804 | 0.77 | ACHE (0.43) | ACHEALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL129762 | 0.77 | ACHE (0.57) | ACHEALDH1A1TDP1CYP3A4MAPT | |
| SCHEMBL30810326 | 0.76 | KDM4E (0.44) | ALDH1A1KDM4ESMN1; SMN2CA2CYP3A4 | |
| SCHEMBL4878432 | 0.76 | KDM4E (0.44) | ALDH1A1KDM4ESMN1; SMN2CA2CYP3A4 | |
| SCHEMBL1530694 | 0.74 | TTR (0.48) | ACHEALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL2955343 | 0.74 | ALDH1A1 (0.56) | ACHEALDH1A1CA2CYP3A4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994117-B1 | HYDROGENATION OF ESTERS TO ALCOHOLS IN THE PRESENCE OF A RU-PNN COMPLEX | BASF SE (DE) | 2024-07-03 | — | — | EP | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-10684294-B2 | Diarylether-based fluorogenic probes for detection of hypochlorous acid or hydroxyl radical | THE UNIVERSITY OF HONG KONG (HK) | 2020-06-16 | — | — | US | disclosed |
| EP-3012250-B1 | ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2404919-B1 | Heterocyclic compound useful as a modulator of ATP-binding cassette transporters. | VERTEX PHARMA (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2395002-A1 | Pharmaceutical composition containing a heterocyclic modulator of ATP-binding cassette transporters. | Vertex Pharmaceuticals Incorporated (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-1581471-B9 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | DABUR RES FOUNDATION (IN) | 2008-08-13 | — | — | EP | disclosed |
| EP-1581471-B1 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | DABUR RES FOUNDATION (IN) | 2008-04-16 | — | — | EP | disclosed |
| US-7179937-B2 | Cyclopentenone derivatives for cancer therapy | DABUR RESEARCH FOUNDATION (IN) | 2007-02-20 | — | — | US | disclosed |
| EP-1581471-A1 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | Dabur Research Foundation (IN) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056738-A1 | CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY | DABUR RESEARCH FOUNDATION (IN) | 2004-07-08 | — | — | WO | disclosed |
| US-20030229146-A1 | Cyclopentenone derivatives for cancer therapy | DABUR RESEARCH FOUNDATION | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10684294-B2 | Diarylether-based fluorogenic probes for detection of hypochlorous acid or hydroxyl radical | HAGH, HADH, FECH | ACHE 3133/4885ALDH1A1 334/4885KDM4E 1598/4885 |
| US-20030229146-A1 | Cyclopentenone derivatives for cancer therapy | MCL1, DLD, PYCR1 | ACHE 4599/4885ALDH1A1 1745/4885KDM4E 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.